liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking
Lund Univ, Sweden.
Lund Univ, Sweden.
Lund Univ, Sweden.
CHU Lille, France; Univ Lille, France.
Show others and affiliations
2020 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 136, no 8, p. 946-956Article in journal (Refereed) Published
Abstract [en]

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene in 13q12.2 are among the most common driver events in acute leukemia, leading to increased cell proliferation and survival through activation of the phosphatidylinositol 3-kinase/AKT-, RAS/MAPK-, and STAT5-signaling pathways. In this study, we examine the pathogenetic impact of somatic hemizygous 13q12.2 microdeletions in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) using 5 different patient cohorts (in total including 1418 cases). The 13q12.2 deletions occur immediately 59 of FLT3 and involve the PAN3 locus. By detailed analysis of the 13q12.2 segment, we show that the deletions lead to loss of a topologically associating domain border and an enhancer of FLT3. This results in increased cis interactions between the FLT3 promoter and another enhancer located distally to the deletion breakpoints, with subsequent allele-specific upregulation of FLT3 expression, expected to lead to ligand-independent activation of the receptor and downstream signaling. The 13q12.2 deletions are highly enriched in the high-hyperdiploid BCP ALL subtype (frequency 3.9% vs 0.5% in other BCP ALL) and in cases that subsequently relapsed. Taken together, our study describes a novel mechanism of FLT3 involvement in leukemogenesis by upregulation via chromatin remodeling and enhancer hijacking. These data further emphasize the role of FLT3 as a driver gene in BCP ALL.

Place, publisher, year, edition, pages
AMER SOC HEMATOLOGY , 2020. Vol. 136, no 8, p. 946-956
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-169994DOI: 10.1182/blood.2019004684ISI: 000565193300008PubMedID: 32384149OAI: oai:DiVA.org:liu-169994DiVA, id: diva2:1470935
Note

Funding Agencies|Swedish Cancer SocietySwedish Cancer Society [CAN 2017/291, CAN 2016/497]; Swedish Childhood Cancer Foundation [TJ2018-0061, PR2018-0004, PR2018-0023]; Swedish Research CouncilSwedish Research Council [2016-01084, 2016-01459]; Ministry of Health of the Czech Republic (Czech Health Research Council) [15-30626A]; University Hospital Motol [00064203]; National Health Service [ALFSKANE-623431]; Royal Physiographic Society of Lund

Available from: 2020-09-26 Created: 2020-09-26 Last updated: 2020-09-26

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sigvardsson, Mikael
By organisation
Division of Molecular Medicine and VirologyFaculty of Medicine and Health Sciences
In the same journal
Blood
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 42 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf